CN101039942A - 磺酰胺类及其用途 - Google Patents

磺酰胺类及其用途 Download PDF

Info

Publication number
CN101039942A
CN101039942A CNA2005800344770A CN200580034477A CN101039942A CN 101039942 A CN101039942 A CN 101039942A CN A2005800344770 A CNA2005800344770 A CN A2005800344770A CN 200580034477 A CN200580034477 A CN 200580034477A CN 101039942 A CN101039942 A CN 101039942A
Authority
CN
China
Prior art keywords
compound
independently
alkyl
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800344770A
Other languages
English (en)
Chinese (zh)
Inventor
J·O·桑德斯
A·纳珀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elixir Pharmaceuticals Inc
Original Assignee
Elixir Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elixir Pharmaceuticals Inc filed Critical Elixir Pharmaceuticals Inc
Publication of CN101039942A publication Critical patent/CN101039942A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2005800344770A 2004-09-27 2005-09-27 磺酰胺类及其用途 Pending CN101039942A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61370004P 2004-09-27 2004-09-27
US60/613,700 2004-09-27

Publications (1)

Publication Number Publication Date
CN101039942A true CN101039942A (zh) 2007-09-19

Family

ID=36119517

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800344770A Pending CN101039942A (zh) 2004-09-27 2005-09-27 磺酰胺类及其用途

Country Status (7)

Country Link
US (1) US20080261970A1 (https=)
EP (1) EP1797090A4 (https=)
JP (1) JP2008514634A (https=)
CN (1) CN101039942A (https=)
CA (1) CA2579242A1 (https=)
MX (1) MX2007003398A (https=)
WO (1) WO2006036932A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
EP2241634A1 (en) * 2009-04-16 2010-10-20 Université Libre de Bruxelles Diagnostic method and tools to predict the effiacy of targeted agents against IGF-1 pathway activation in cancer
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2917511A (en) * 1958-01-30 1959-12-15 Merck & Co Inc Bicyclic-nitrogen-heterocyclic compounds
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
CA2561801A1 (en) * 2004-04-02 2005-10-20 Elixir Pharmaceuticals, Inc. Sulfonamides and uses thereof

Also Published As

Publication number Publication date
US20080261970A1 (en) 2008-10-23
CA2579242A1 (en) 2006-04-06
EP1797090A4 (en) 2009-11-11
MX2007003398A (es) 2007-05-21
WO2006036932A3 (en) 2006-06-22
JP2008514634A (ja) 2008-05-08
EP1797090A2 (en) 2007-06-20
WO2006036932A2 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
US7897765B2 (en) Therapeutic compounds and uses thereof
US20110152232A1 (en) Sulfonamide compounds and uses thereof
US20050261332A1 (en) Sulfonamides and uses thereof
US20120088747A1 (en) Sulfonamide containing compounds and uses thereof
CN1264384A (zh) 稠合1,2,4-噻二嗪衍生物及其制备方法和用途
CN1276790A (zh) 酰胺基噻唑衍生物及其制备方法与药物组合物
JP2008545010A (ja) Ｇタンパク質共役受容体アゴニスト
CN1726189A (zh) 新颖的mch受体拮抗剂
US11046660B2 (en) Compounds and their use as PDE4 activators
US20180057466A1 (en) Triazole derivatives and their use as pde4 activators
CN1791409A (zh) 作为 p p a r调节剂的 ( 3 －{ 3'－ [ ( 2 , 4 －双 －三氟甲基 －苄基)－ ( 5 －乙基 －嘧啶 － 2 －基 )－氨基 ]－丙氧基} －苯基) －乙酸及相关化合物以及治疗代谢失调的方法
CN101039942A (zh) 磺酰胺类及其用途
CN1771231A (zh) 钙受体调节性化合物及其用途
CN1216547A (zh) 质子泵抑制剂
US20060293370A1 (en) Sulfonamide compounds and uses thereof
CN1918155A (zh) 作为lxr调节剂的化合物和组合物
WO2010104967A1 (en) Sulfonamide containing compounds and uses thereof
CN1053919A (zh) 新的咪唑化合物，其制备方法和基于这些化合物的药剂以及某些中间产物
WO2010104929A1 (en) Sulfonamide containing compounds and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20070919